Ebola outbreak in DRC: response efforts struggle to keep pace with escalating crisis

Five weeks after its declaration, the Ebola Bundibugyo outbreak in the Democratic Republic of Congo remains uncontained. While response efforts have intensified significantly, the virus continues to spread, cross borders, and claim lives at an alarming rate.

Escalation of response measures

Healthcare capacity has expanded dramatically, with treatment beds increasing from fewer than 10 to over 500 across 19 facilities in affected zones. Testing capacity has surged from just 30 daily tests at the onset to over 2,000 per day across nine laboratories spanning three provinces. More than 100 recoveries have been recorded, demonstrating that early intervention can make a critical difference. Yet the overall toll remains devastating: 1,094 confirmed cases and 277 deaths to date.

According to the WHO Director-General, Tedros Adhanom Ghebreyesus, “the epidemic continues to outpace the response.” Contact tracing remains inadequate, isolation capacities fall short of needs, and secure burials remain a daily challenge in communities that are often mistrustful or inaccessible.

Cross-border spread raises alarm

The outbreak has now spilled beyond the Congolese provinces of Ituri, North Kivu, and South Kivu. Neighboring Uganda has reported 20 confirmed cases and two deaths, all linked to the Congolese strain. Even more concerning, France confirmed its first case on European soil this week: a humanitarian doctor from ALIMA, returning from a mission in DRC, tested positive for the Bundibugyo Ebola virus. The patient, currently in stable condition in a specialized facility, is undergoing epidemiological monitoring to trace and monitor contacts.

This case underscores the heavy price paid by frontline healthcare workers. Nearly 80 health workers have been infected since the crisis began, prompting the WHO to urge states to ensure secure deployment conditions for humanitarian personnel, including the possibility of rapid medical evacuation in case of contamination.

Structural barriers hinder containment

Beyond health challenges, the response faces structural constraints that impede every intervention. Border closures restrict the movement of teams and equipment. Security incidents are on the rise in a region plagued by decades of armed conflict. And funding is slow to materialize, despite a continental plan launched by WHO and Africa CDC totaling $518 million.

A ray of hope emerges: a clinical trial evaluating two antivirals, MBP134 and remdesivir, is set to begin next week in DRC. Led by a consortium including the Congolese Institut National de Recherche Biomédicale, ALIMA, Oxford University, and WHO, and supported by donations from the United States and Gilead Sciences, this trial could mark a decisive turning point in the fight against an epidemic that, five weeks after its declaration, shows no signs of abating.